Patent expiry and costs for anti-cancer medicines for clinical use

Brian Godman; Claudia Wild; Alan Haycox

doi:10.5639/gabij.2017.0603.021

Patent expiry and costs for anti-cancer medicines for clinical use

Brian Godman
, Claudia Wild
, Alan Haycox

University of Strathclyde
Karolinska Institutet
University of Liverpool
Ludwig Boltzmann Institute

Research output: Contribution to journal › Comment/debate

24 Scopus citations

Abstract

Venkatesan S et al. have researched patent rights and pricing for (non-)tyrosine kinase inhibitors. It is not clear why the patent rights are so long and why prices of (non-)tyrosine kinase inhibitors can be high. These issues are discussed.

Original language	English
Pages (from-to)	105-106
Number of pages	2
Journal	GaBI Journal
Volume	6
Issue number	3
DOIs	https://doi.org/10.5639/gabij.2017.0603.021
State	Published - 2017
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cancer medicines
Generics
Health gain
Prices
Tyrosine kinase inhibitors (TKI)

Access to Document

10.5639/gabij.2017.0603.021

Cite this

@article{354bd4f7c2df45588f8bb04f25025003,

title = "Patent expiry and costs for anti-cancer medicines for clinical use",

abstract = "Venkatesan S et al. have researched patent rights and pricing for (non-)tyrosine kinase inhibitors. It is not clear why the patent rights are so long and why prices of (non-)tyrosine kinase inhibitors can be high. These issues are discussed.",

keywords = "Cancer medicines, Generics, Health gain, Prices, Tyrosine kinase inhibitors (TKI)",

author = "Brian Godman and Claudia Wild and Alan Haycox",

note = "Publisher Copyright: {\textcopyright} 2017 Pro Pharma Communications International.",

year = "2017",

doi = "10.5639/gabij.2017.0603.021",

language = "English",

volume = "6",

pages = "105--106",

journal = "GaBI Journal",

issn = "2033-6403",

publisher = "Pro Pharma Communications International",

number = "3",

}

TY - JOUR

T1 - Patent expiry and costs for anti-cancer medicines for clinical use

AU - Godman, Brian

AU - Wild, Claudia

AU - Haycox, Alan

PY - 2017

Y1 - 2017

N2 - Venkatesan S et al. have researched patent rights and pricing for (non-)tyrosine kinase inhibitors. It is not clear why the patent rights are so long and why prices of (non-)tyrosine kinase inhibitors can be high. These issues are discussed.

AB - Venkatesan S et al. have researched patent rights and pricing for (non-)tyrosine kinase inhibitors. It is not clear why the patent rights are so long and why prices of (non-)tyrosine kinase inhibitors can be high. These issues are discussed.

KW - Cancer medicines

KW - Generics

KW - Health gain

KW - Prices

KW - Tyrosine kinase inhibitors (TKI)

UR - https://www.scopus.com/pages/publications/85033362837

U2 - 10.5639/gabij.2017.0603.021

DO - 10.5639/gabij.2017.0603.021

M3 - Comment/debate

AN - SCOPUS:85033362837

SN - 2033-6403

VL - 6

SP - 105

EP - 106

JO - GaBI Journal

JF - GaBI Journal

IS - 3

ER -

Patent expiry and costs for anti-cancer medicines for clinical use

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this